Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – February 9, 2022 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call - Dr. Wilcox

DUR Board Members:

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Markita Broyles –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 952 7560 1667
Passcode: 69395211

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. December 8, 2021 DUR Board Meeting Minutes
   B. December 8, 2021 DUR Board Recommendations Memorandum
   C. January 12, 2022 DUR Board Recommendations Memorandum

Items to be presented by Dr. Ha, Dr. Nawaz, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/Use of Glucagon-Like Peptide-1 (GLP-1) Agonists or Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors with Cardiovascular (CV) Benefit in Members with Type 2 Diabetes (T2D) and High CV Risk or Established Atherosclerotic CV Disease (ASCVD) Mailing Update – See Appendix B**
   A. Pharmacy Helpdesk Activity for January 2022
   B. Medication Coverage Activity for January 2022
   C. Use of GLP-1 Agonists or SGLT-2 Inhibitors with CV Benefit in Members with T2D and High CV Risk or Established ASCVD Mailing Update

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

5. **Narrow Therapeutic Index (NTI) List – See Appendix C**
   A. Introduction
   B. SoonerCare NTI Drug List
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Livmarli™ (Maralixibat) – See Appendix D**
   A. Market News and Updates
   B. Livmarli™ (Maralixibat) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Myfembree® (Relugolix/Estradiol/ Norethindrone) – See Appendix E**
   A. Market News and Updates
   B. Myfembree® (Relugolix/Estradiol/Norethindrone) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Sertraline Capsules and Update the Approval Criteria for the Antidepressants – See Appendix F**
   A. Market News and Updates
   B. Sertraline Capsules Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

9. **Action Item – Vote to Prior Authorize Tyrvana™ (Varenicline Nasal Spray) and Update the Approval Criteria for the Dry Eye Disease (DED) Medications – See Appendix G**
   A. Market News and Updates
   B. Tyrvana™ (Varenicline Nasal Spray) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

10. **Action Item – Vote to Prior Authorize Byooviz™ (Ranibizumab-nuna Intravitreal Injection) and Susvimo™ (Ranibizumab Intravitreal Implant) – See Appendix H**
    A. Market News and Updates
    B. Byooviz™ (Ranibizumab-nuna Intravitreal Injection) Product Summary
    C. Susvimo™ (Ranibizumab Intravitreal Implant) Product Summary
    D. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

11. **Action Item – Vote to Update the Approval Criteria for the Glaucoma Medications – See Appendix I**
    A. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

12. **Action Item – Vote to Prior Authorize Empaveli™ (Pegcetacoplan) – See Appendix J**
    A. Market News and Updates
    B. Empaveli™ (Pegcetacoplan) Product Summary
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

13. **Action Item – Vote to Prior Authorize Evkeeza® (Evinacumab-dgnb) and Leqvio® (Inclisiran) and Update the Approval Criteria for the Antihyperlipidemics – See Appendix K**
    A. Market News and Updates
    B. Evkeeza® (Evinacumab-dgnb) Product Summary
    C. Leqvio® (Inclisiran) Product Summary
    D. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

14. **Action Item – Annual Review of Arcalyst® (Rilonacept) – See Appendix L**
    A. Current Prior Authorization Criteria
    B. Utilization of Arcalyst® (Rilonacept)
    C. Prior Authorization of Arcalyst® (Rilonacept)
    D. Market News and Updates
    E. Cryopyrin-Associated Periodic Syndromes (CAPS)
    F. Arcalyst® (Rilonacept) Product Summary
    G. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

15. **Annual Review of Leukemia Medications and 30-Day Notice to Prior Authorize Erwinase® (Crisantaspase), Erwinaze® (Asparaginase *Erwinia Chrysanthemi*), Oncaspar® (Pegaspargase), Rylaze™ [Asparaginase *Erwinia Chrysanthemi* (Recombinant)-rywn], and Scemblix® (Asciminib) – See Appendix M**
    A. Current Prior Authorization Criteria
    B. Utilization of Leukemia Medications
    C. Prior Authorization of Leukemia Medications
    D. Market News and Updates
    E. Product Summaries
    F. College of Pharmacy Recommendations
    G. Utilization Details of Leukemia Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

16. **Annual Review of Azedra® (Iobenguane I-131) – See Appendix N**
    A. Current Prior Authorization Criteria
    B. Utilization of Azedra® (Iobenguane I-131)
    C. Prior Authorization of Azedra® (Iobenguane I-131)

D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Azedra® (Iobenguane I-131)

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

17. Annual Review of Anticonvulsants and 30-Day Notice to Prior Authorize Elepsia™ XR [Levetiracetam Extended-Release (ER) Tablet] and Eprontia™ (Topiramate Oral Solution) – See Appendix O

A. Current Prior Authorization Criteria
B. Utilization of Anticonvulsants
C. Prior Authorization of Anticonvulsants
D. Market News and Updates
E. Elepsia™ XR (Levetiracetam ER) Product Summary
F. Eprontia™ (Topiramate Oral Solution) Product Summary
G. College of Pharmacy Recommendations
H. Utilization Details of Anticonvulsants

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

18. Annual Review of Anti-Migraine Medications and 30-Day Notice to Prior Authorize Qulipta™ (Atogepant) and Trudhesa™ (Dihydroergotamine Nasal Spray) – See Appendix P

A. Current Prior Authorization Criteria
B. Utilization of Anti-Migraine Medications
C. Prior Authorization of Anti-Migraine Medications
D. Market News and Updates
E. Qulipta™ (Atogepant) Product Summary
F. Trudhesa™ (Dihydroergotamine Nasal Spray) Product Summary
G. College of Pharmacy Recommendations
H. Utilization Details of Anti-Migraine Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

19. Annual Review of Topical Acne and Rosacea Products and 30-Day Notice to Prior Authorize Winlevi® (Clascoterone 1% Cream) – See Appendix Q

A. Current Prior Authorization Criteria
B. Utilization of Topical Acne and Rosacea Products
C. Prior Authorization of Topical Acne and Rosacea Products
D. Market News and Updates
E. Winlevi® (Clascoterone 1% Cream) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Topical Acne and Rosacea Products

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

20. 30-Day Notice to Prior Authorize Dojolvi® (Triheptanoin) – See Appendix R

A. Introduction
B. Dojolvi® (Triheptanoin) Product Summary

C. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

21. Annual Review of Zokinvy™ (Lonafarnib) – See Appendix S

A. Current Prior Authorization Criteria
B. Utilization of Zokinvy™ (Lonafarnib)
C. Prior Authorization of Zokinvy™ (Lonafarnib)
D. Market News and Updates
E. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

22. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix T

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

23. Future Business* (Upcoming Product and Class Reviews)

A. Granulocyte Colony-Stimulating Factors (G-CSFs)
B. Growth Hormone Products
C. Hemophilia Medications
D. Lymphoma Medications

*Future product and class reviews subject to change.

24. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.